Back to Browse Journals » Clinical Interventions in Aging » Volume 2 » Issue 1

Full length parathyroid hormone (1–84) in the treatment of osteoporosis in postmenopausal women

Authors Esteban Jódar-Gimeno

Published 15 April 2007 Volume 2007:2(1) Pages 163—174

Esteban Jódar-Gimeno

Endocrinology and Metabolism Service, University Hospital “12 de Octubre”, Madrid, Spain. Associate Professor of Medicine Universidad Complutense, Madrid, Spain

Objective: To review the pharmacological properties and the available clinical data of full length parathyroid hormone (PTH) in post-menopausal osteoporosis.

Sources: A MEDLINE search was completed, together with a review of information obtained from the manufacturer and from the medicine regulatory agencies.

Study and data selection: Studies were selected according to relevance and availability. Relevant information (design, objectives, patients’ characteristics, outcomes, adverse events, dosing, etc) was analyzed.

Results: Different studies have shown that, when administered intermittently as a subcutaneous injection in the abdomen, PTH increases bone mineral density (BMD) and prevents vertebral fractures. On completion of PTH therapy (up to 24 months), there is evidence that sequential treatment with alendronate is associated with a therapeutic benefit in terms of increase in BMD. Further trials are necessary to determine long-term safety and the role of PTH in combination with other treatments for osteoporosis and the effect of repeated cycles of PTH followed by an anti-catabolic agent. There are currently no completed comparative trials with other osteoporosis treatments.

Conclusions: Full length PTH, given intermittently as an abdominal subcutaneous injection, appears to be a safe and efficacious treatment option for high risk osteoporosis. More data are needed to determine its specific role in osteoporosis treatment.

Keywords: postmenopausal osteoporosis, anabolic therapy, PTH (1–84)

Download Article [PDF] 

Readers of this article also read:

Use of palivizumab is underestimated in the Swedish Prescribed Drug Register – implications for register-based drug studies

Linder M, BystrΓΆm C, Kieler H, Bergman G, Haerskjold A

Clinical Epidemiology 2015, 7:45-51

Published Date: 29 December 2014

Associations between apolipoprotein E genotypes and serum levels of glucose, cholesterol, and triglycerides in a cognitively normal aging Han Chinese population

Tao QQ, Chen Y, Liu ZJ, Sun YM, Yang P, Lu SJ, Xu M, Dong QY, Yang JJ, Wu ZY

Clinical Interventions in Aging 2014, 9:1063-1067

Published Date: 9 July 2014

Virgin olive oil blended polyurethane micro/nanofibers ornamented with copper oxide nanocrystals for biomedical applications

Amna T, Hassan MS, Yang J, Khil MS, Song KD, Oh JD, Hwang I

International Journal of Nanomedicine 2014, 9:891-898

Published Date: 13 February 2014

Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo [Corrigendum]

Xiang DX, Zheng Y, Duan W, Li XJ, Yin JJ, Shigdar S, O'Connor ML, Marappan M, Zhao XJ, Miao YQ, Xiang B, Zheng CL

International Journal of Nanomedicine 2013, 8:4703-4704

Published Date: 5 December 2013

Microincisional vitrectomy for retinal detachment in I-125 brachytherapy-treated patients with posterior uveal malignant melanoma

Lonngi M, Houston SK, Murray TG, Sisk RA, Decatur CL, Cavalcante M, Markoe AM

Clinical Ophthalmology 2013, 7:427-435

Published Date: 27 February 2013

Persistent high fever and systemic inflammation induced by percutaneous coronary intervention-related periaortitis

Takamori Kakino, Tomohiro Nakayama, Hideo Yamamoto

Vascular Health and Risk Management 2009, 5:1059-1062

Published Date: 8 December 2009

Nebivolol in the treatment of chronic heart failure

Angie Veverka, Jennifer L Salinas

Vascular Health and Risk Management 2007, 3:647-654

Published Date: 15 November 2007